Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Immunosuppressants Stories

2013-05-29 23:25:36

Breakthrough Treatment Offers New Hope for the Brain Injured. (PRWEB) May 29, 2013 Neurological Recovery Guide and Neurological Wellness Center have been facilitating recovery from traumatic brain injury (TBI) since 2010. U.S. service persons, their spouses or caregivers will be greeted at the airport, chauffeured in our limousine to our Neurological Wellness Center for evaluation, treatment and caregiver training. Service persons who are unable to travel to our Neurological Wellness Center...

2013-05-30 00:20:34

-- At six months, adjusted mean treatment satisfaction scores increased by a statistically significant 20.4 with Gilenya vs. 2.9 with injectable disease modifying therapies1 EAST HANOVER, N.J., May 30, 2013 /PRNewswire/ -- People with relapsing multiple sclerosis (MS) reported greater treatment satisfaction after starting the oral treatment Gilenya(®) (fingolimod) vs. switching to, or staying on, injectable interferon beta or glatiramer acetate, according to new study data...

2013-05-27 04:20:27

Company Receives CE Mark for COMBO Dual Therapy Stent(TM); Introduces Product in Europe and Markets in Asia Pacific and Middle East Regions HONG KONG, May 27, 2013 /PRNewswire/ -- OrbusNeich today launched the world's first dual therapy stent - the COMBO Dual Therapy Stent - to address the challenges of delayed healing of the coronary artery associated with monotherapy drug eluting stents (DES), the current standard of care for the treatment of coronary artery disease (CAD). The...

2013-05-26 08:20:18

SINGAPORE, May 26, 2013 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, today announced the completion of its acquisition of substantially all assets of Spectrum Dynamics, a leader in advanced functional assessment technologies, including those used to evaluate patients for cardiac interventions. The deal consideration is approximately...

2013-05-24 13:54:15

University of Montreal researchers have discovered a novel molecular mechanism that can potentially slow the progression of some cancers and other diseases of abnormal growth. In the May 23 edition of the prestigious journal Cell, scientists from the University of Montreal explain how they found that the anti-cancer and anti-proliferative drug rapamycin slows down or prevents cells from dividing. “Cells normally monitor the availability of nutrients and will slow down or accelerate...

2013-05-22 23:23:56

Novel drug treatment facilitates recovery of memory, mood and cognitive function. The improved self-suficiency enables a lower level of care according to a recent NWC observational study. (PRWEB) May 22, 2013 Neurological Recovery Guide and Neurological Wellness Center have been facilitating recovery from Alzheimer's disease since 2010.This breakthrough therapy results in rapid cognitive improvement by reducing inflammation in the brain. A growing body of published research has linked...

2013-05-22 16:24:56

- New data demonstrate a critical relationship between antibodies to adalimumab (ATA) and clinical response in IBD patients - SAN DIEGO, May 22, 2013 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the eighteen abstracts relating to its proprietary diagnostic platform were presented at Digestive Disease Week (DDW) 2013. The abstracts (see full list below) highlight Prometheus' innovative technologies aimed at...

2013-05-22 08:29:49

PARIS, May 22, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) reports positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies, which are emerging treatment options for coronary heart disease. Data from the first human use NG PROMUS Clinical Trial evaluating the safety and effectiveness of the Promus PREMIER(TM) Everolimus-Eluting Platinum Chromium Coronary Stent System, and two-year follow-up data from the EVOLVE Trial comparing the...

2013-05-21 16:27:48

HORSHOLM, Denmark, May 21, 2013 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that the European Medicines Agency (EMA) accepted for review the company's Marketing Authorization Application (MAA) to market LCP-Tacro for the prevention of organ rejection in kidney transplant patients in the European Union. Veloxis expects the decision from the European Union in 2014. For Investor and media contact: John Weinberg, M.D. EVP & Chief Commercial Officer Phone: +1 732...

2013-05-21 08:28:47

- XIENCE Xpedition(TM) 48 Leverages Proven Design and Clinical Outcomes of the XIENCE Family of Drug Eluting Stents ABBOTT PARK, Ill., May 21, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today announced CE Mark in Europe for the XIENCE Xpedition(TM) 48 Everolimus Eluting Coronary Stent System, the first-of-its-kind treatment for very long blockages in the vessels that supply blood to the heart due to coronary artery disease (CAD). XIENCE Xpedition 48 leverages the proven design and...